argenx SE Investor Day Presentation Deck
Idiopathic Inflammatory Myopathy (IIM) or Myositis
Rare, severe autoimmune disorders characterized by chronic muscle inflammation, pain and impaired quality of life; no FDA-approved
therapies for myositis
PREVALENCE
14 per 100,000
Mid-adult onset
More common
in females
argenx
MYOSITIS IS MEDIATED BY AUTOANTIBODIES
HALLMARK
Proximal muscle weakness is
unifying feature of myositis subsets
TREATMENT
No consensus guidelines for
management
Treated primarily by
rheumatologists and neurologists
BURDEN
(1) Meyer et al., Rheumatology. 2015; (2) Pinal-Fernandez et al., Curr Rheumatol Rep. 2018; (3) Schmidt, Journal of Neuromuscular Diseases. 2018
High impact on quality of life:
muscle atrophy, pain, functional
impairment, dysphagia, dyspnea
High mortality rate: malignancy,
interstitial lung disease and
infections
Myositis subsets mediated by autoantibodies: immune-mediated necrotizing myopathy (IMNM),
anti-synthetase syndrome (ASyS), and dermatomyositis (DM)
Significant market opportunity with ~33K eligible patients in the U.S.
24View entire presentation